Armata Pharmaceuticals (ARMP) Current Deferred Revenue (2016 - 2017)
Historic Current Deferred Revenue for Armata Pharmaceuticals (ARMP) over the last 5 years, with Q3 2017 value amounting to $20000.0.
- Armata Pharmaceuticals' Current Deferred Revenue rose 1111.11% to $20000.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $20000.0, marking a year-over-year increase of 1111.11%. This contributed to the annual value of $245000.0 for FY2015, which is 40.98% up from last year.
- Latest data reveals that Armata Pharmaceuticals reported Current Deferred Revenue of $20000.0 as of Q3 2017, which was up 1111.11% from $58000.0 recorded in Q2 2017.
- In the past 5 years, Armata Pharmaceuticals' Current Deferred Revenue registered a high of $350000.0 during Q2 2015, and its lowest value of $18000.0 during Q3 2016.
- In the last 5 years, Armata Pharmaceuticals' Current Deferred Revenue had a median value of $142000.0 in 2015 and averaged $171600.0.
- As far as peak fluctuations go, Armata Pharmaceuticals' Current Deferred Revenue tumbled by 9271.26% in 2016, and later soared by 3488.37% in 2017.
- Quarter analysis of 5 years shows Armata Pharmaceuticals' Current Deferred Revenue stood at $244000.0 in 2013, then changed by 0.0% to $244000.0 in 2014, then grew by 0.41% to $245000.0 in 2015, then plummeted by 92.65% to $18000.0 in 2016, then increased by 11.11% to $20000.0 in 2017.
- Its Current Deferred Revenue was $20000.0 in Q3 2017, compared to $58000.0 in Q2 2017 and $86000.0 in Q1 2017.